Log In
BCIQ
Print this Print this
 

biosimilar adalimumab (BX2992)

  Manage Alerts
Collapse Summary General Information
Company BioXpress Therapeutics S.A.
DescriptionBiosimilar of adalimumab, an anti tumor necorisis factor (TNF) alpha mAb
Molecular Target Tumor necrosis factor (TNF) alpha
Mechanism of ActionAntibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat rheumatoid arthritis (RA)
Regulatory Designation
PartnerAlfred E. Tiefenbacher GmbH & Co. KG

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/05/2012

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today